Study Monitoring Adults Treated for Venous Thromboembolic Disease to Track Recurrence and Bleeding Risks

What this Trial Is About

Venous thromboembolic disease is a common condition affecting many people, with the risk of recurrence largely depending on whether the initial blood clot was provoked by a known factor. Patients who have unprovoked thromboembolic events face a higher chance of recurrence, leading clinicians to often continue anticoagulant treatments long-term. However, these treatments carry risks such as bleeding and are a leading cause of hospitalization due to side effects, so balancing treatment benefits and risks is crucial. This research evaluates tools used to guide treatment decisions for patients with venous thromboembolic disease, including bleeding risk scores like HAS BLED and VTE BLED, and recurrence risk scores such as HERDOO2. Since 2015, multidisciplinary thrombosis meetings have been held to support clinicians in managing complex cases, along with dedicated post-emergency consultations for less severe patients. Participants in this observational study who have had at least one venous thromboembolic event will be followed for up to 12 years. Researchers will monitor rates of recurrence and bleeding complications, as well as long-term complications, through initial enrollment and regular follow-up visits. The study aims to improve patient management by assessing the usefulness of these risk scores and multidisciplinary approaches in real-world care.

Cohort for Monitoring Patients With Venous Thromboembolic Disease